Oct. 18 at 1:03 PM
$SCNX After receiving FDA approval for Arbli™, the first-ever ready-to-use liquid Losartan, Scienture Holdings entered a rare category- a de-risked, revenue-ready biotech transitioning into full commercialization.
With the product now rolling out through a 2,500-facility GPO network, the company has moved from R&D to cash-flow visibility, a phase where strategic partnerships and acquisitions typically occur.
Large pharma and specialty companies constantly scout for FDA-approved niche formulations that solve unmet patient needs and Arbli™ does just that, addressing millions who cannot swallow tablets.
In today’s market, where pipeline de-risking is priority, SCNX offers a turnkey asset: regulatory-cleared, scalable, and institutionally adopted making it a natural acquisition target for several industry players positioned to amplify its reach globally.
$DRUG $TVGN
Here are some potential acquirers :
